source
- Novartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustmentDespite a bumpy few months for Novartis that saw a couple of high-profile clinical setbacks, CEO Vas Narasimhan has told Fierce he believes most shareholders remain onside with the company’s strategy.Fierce Biotech · 7h ago↗ source
- FDA approves Infilbray, first therapy for neurological symptoms of Type 3 Gaucher diseaseThe U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets for treating the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15…